What are the investigator's responsibilities under ICH E6(R3)?

The investigator is responsible for the conduct of the trial at the site and for the participants in their care: they must be qualified, have the time, staff and facilities the trial needs, follow the protocol, obtain informed consent, provide medical care and report safety events, and keep accurate records (ICH E6(R3) 2.1.1).

The investigator can delegate tasks but never the responsibility, which stays with them and is shown through oversight proportionate to the risk of each task (ICH E6(R3) 2.3.1).

The responsibilities, section by section

  • Qualifications and training: qualified by education, training and experience, with evidence of it, and familiar with the investigational product (ICH E6(R3) 2.1.1).
  • Resources: enough time, qualified staff and adequate facilities for the whole trial (ICH E6(R3) 2.2.2).
  • Delegation and oversight: delegated people are qualified and informed, and a record of delegation is kept (ICH E6(R3) 2.3.2).
  • IRB or ethics committee: a documented, dated favorable opinion before the trial starts (ICH E6(R3) 2.4.2).
  • Protocol: follow it, and document all deviations (ICH E6(R3) 2.5.3).
  • Medical care and safety: adequate care for adverse events (ICH E6(R3) 2.7.1(c)), and serious adverse events to the sponsor immediately (ICH E6(R3) 2.7.2(b)).
  • Informed consent: obtained and documented before participation (ICH E6(R3) 2.8.7).
  • Investigational product: storage and records of receipt, use and return (ICH E6(R3) 2.10.4).
  • Records: accurate source records and reported data, essential records retained for the required period (ICH E6(R3) 2.12.12).
  • Access: permit monitoring, audits and inspections (ICH E6(R3) 2.3.5).

The US regulations behind the guideline

For drug studies under an IND, the investigator is responsible for conducting the study according to the signed investigator statement, the investigational plan and the regulations, for protecting the rights, safety and welfare of subjects, and for control of the drug (21 CFR 312.60).

The signed investigator statement, the Form FDA 1572, commits the investigator to personally conduct or supervise the investigation and to make sure everyone assisting knows their obligations (21 CFR 312.53(c)).

Where investigators get into trouble

The most common pattern is not ignorance of a rule but oversight that exists only on paper: tasks delegated to people without the right training, safety data from external labs nobody reviewed in time, or a delegation log no one updated. E6(R3) makes the investigator responsible for timely review of data that can affect eligibility, treatment or safety, including data from central laboratories (ICH E6(R3) 2.12.3).

Questions people also ask

Can the principal investigator delegate everything?

The investigator may delegate trial-related activities but keeps the ultimate responsibility and must oversee them in proportion to their importance and risk (ICH E6(R3) 2.3.1). Medical decisions stay with a qualified physician or other qualified healthcare professional who is an investigator (ICH E6(R3) 2.7.1(a)).

What is a sub-investigator?

A member of the trial team designated by and working under the oversight of the investigator to perform significant trial procedures or make important trial decisions, for example associates, residents or research fellows (ICH E6(R3) Glossary).

What does an investigator have to keep after the trial?

The essential records, for the period the regulations require or until the sponsor says they are no longer needed, whichever is longer (ICH E6(R3) 2.12.12). For US drug studies see 21 CFR 312.62(c).

Who decides whether an adverse event is related to the study drug?

The investigator, who sends serious adverse events to the sponsor immediately with a causality assessment (ICH E6(R3) 2.7.2(b)).

Primary sources

  • ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025 (ICH): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
  • 21 CFR 312.60: General responsibilities of investigators (eCFR): https://www.ecfr.gov/current/title-21/section-312.60
  • 21 CFR 312.53: Selecting investigators and monitors (eCFR): https://www.ecfr.gov/current/title-21/section-312.53

Last reviewed

2026-11-12